EXHIBIT 99.1

(ADAMS RESPIRATORY THERAPEUTICS LOGO)
ADAMS RESPIRATORY THERAPEUTICS REPORTS
FISCAL 2006 THIRD QUARTER FINANCIAL RESULTS
     Excellent financial performance driven by strong market penetration of the Mucinex® franchise
Third Quarter Financial Highlights:
    Net sales increased 29% to $76.0 million.
 
    Pretax income increased 13% to $27.6 million.
 
    Income per diluted share increased to $0.46, including a one-time pretax charge of $1.5 million or $0.03 per diluted share recorded in connection with moving the corporate headquarters.
Other Highlights:
    Mucinex® franchise gained nearly 4 market share points during the 2005-2006 cough/cold season and became the No. 2 product in the cough/cold/allergy/sinus category, according to Information Resources Inc. (IRI) weekly consumption data thru Mar. 19, 2006, and monthly brand data for the 12-weeks ended Mar. 19, 2006.
 
    Launched a new advertising campaign for Mucinex® D on Feb. 23, targeting sufferers of congested allergies. Initial consumer response to Mucinex® D is encouraging.
 
    Commenced Phase IIb clinical program for erdosteine in late March.
 
    Made solid progress in manufacturing and increased production.
 
    Relocated Adams’ corporate headquarters in April 2006 to a larger facility in Chester, N.J.
 
    Initiated plans for a sales force expansion to be completed in July 2007.
CHESTER, N.J. (May 11, 2006) – Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT) today announced financial results for the fiscal third quarter ended Mar. 31, 2006.
Commenting on the results for the quarter, Michael J. Valentino, president & CEO said, “This has been a quarter of excellent financial performance driven by strong market penetration of the Mucinex® franchise. Successful execution in the marketplace was also a key contributor. We made solid progress in manufacturing and increased production at a newly qualified Cardinal facility in Winchester, KY. This allowed us to produce and ship product in excess of our previously stated topline guidance of between $72 and $75 million for the fiscal 2006 third quarter. We also successfully started to penetrate the allergy category with Mucinex® D during the quarter, despite new regulatory constraints that restrict access and limit secondary product placement at retail. As expected during the quarter, we also initiated a Phase IIb clinical program for erdosteine, a unique mucoregulator compound.”

 


The following information was filed by Adams Respiratory Therapeutics, Inc. on Thursday, May 11, 2006 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Adams Respiratory Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adams Respiratory Therapeutics, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account